Document:

EX-10.9

 Exhibit 10.9 

Amendment No. 5 to Collaboration and License Agreement 

This Amendment No. 5 to Collaboration and License Agreement (this “Amendment No. 5”) is made and effective as of
July 31, 2016, by and between Proteostasis Therapeutics, Inc., a corporation existing under the laws of the State of Delaware, having a place of business at 200 Technology Square, 4th
Floor, Cambridge, MA 02139 (“PTI”) and Astellas Pharma Inc., a Japanese corporation having its principal place of business at 5-1 Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8411, Japan
(“Astellas”). Each of Astellas and PTI is sometimes referred to individually herein as a “Party” and collectively as the “Parties”. 

Reference is hereby made to that certain Collaboration and License Agreement dated November 4, 2014 and amended on May 1,
2015, August 5, 2015, December 1, 2016, and January 31, 2016, by and between the Parties (the “Agreement”).  Capitalized terms used, but not defined herein shall have the meanings ascribed to
such terms in the Agreement. 
 WHEREAS, the Parties now wish to further amend the Agreement pursuant to the terms and conditions set forth
herein; 
 NOW, THEREFORE, in consideration of the premises, the mutual covenants contained herein and other valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 
 1. Section 5.2(b) is deleted in its
entirety and replaced with the following language: 
 “(b) Responsibilities of the JRC. The JRC will: 

(i) review the Research Plan, including the Research Budget, for each Project; 

(ii) discuss progression of the Active Compounds (but not Discontinued Compounds) through each phase in accordance with the
Research Plan for each Project; 
 (iii) establish and monitor progress against the objectives of the Research Plan for each
Project; 
 (iv) review and approve any revisions to the Research Plan for each Project, including the Research Budget,
proposed by either Party from time to time as needed; 
 (v) exchange and review scientific information and data relating to
the activities being conducted under the Research Plan for each Project; 
 (vi) assess the results of each of the Disease
Selection Phase, the HTS Phase and the Optimization Phase and present its assessment to Astellas; 
 (vii) determine if the
criteria defined in the Research Plan as amended with respect to the Initial Project pursuant to Section 2.3(b) for nine (9) months, twelve (12) months, and eighteen (18) months, 

  
 1 

 
respectively, after the designation of Hit Series by Astellas (Nine (9)-Month Criteria, Twelve (12)-Month Criteria, and Eighteen (18)-Month Criteria, respectively) are achieved; and 

(viii) make such other decisions as are expressly allocated to the JRC under this Agreement.” 

2. Section 12.2(b)(ii) is deleted in its entirety and replaced with the following language: 

“(ii) Project Termination. Notwithstanding aforementioned, Astellas may also terminate this Agreement on a Project-by-project
basis, in its sole discretion, by providing written notice of termination to PTI: 
 (A) within twenty (20) Business
Days following presentation of the results from each of the Disease Selection Phase (with respect to any Additional Projects) and the HTS Phase to the JRC; 

(B) with respect to any Additional Projects, if the Disease Selection Phase is not completed in accordance with the objectives
set forth in the then-current Research Plan within three (3) months from the date specified for completion of such phase in such then-current Research Plan; 

(C) if the HTS Phase is not completed in accordance with the objectives set forth in the then-current Research Plan within six
(6) months from the date specified for completion of such phase in such then-current Research Plan; 
 (D) if JRC
determined Nine (9)-Month Criteria, Twelve (12)-Month Criteria or Eighteen (18)-Month Criteria in the then-current Research Plan are not achieved in accordance with Section 5.2(b)(vii); or 

(E) within sixty (60) days following presentation of the results of the Optimization Phase to the JRC. 

In the event that Astellas does not terminate a Project during the Research Term pursuant to paragraphs (B) and (C) of this
Section 12.2(b)(ii) (Project Termination) above, Astellas will continue to fund the Project through the immediately following phase of the Project in accordance with Section 6.2 (Research Expenses).” 

3. Except as amended hereby, all other terms of the Agreement shall remain unchanged and in full force and effect. 

4. This Amendment No. 5 will be governed by, and construed in accordance with, the laws of the state of New York, without taking into
consideration any choice of law principles that would lead to the application of the laws of another jurisdiction. 

  
 2 

 IN WITNESS WHEREOF, the Parties have caused this Amendment No. 5 to be executed by their duly authorized
representatives. 
  

									
	ASTELLAS PHARMA INC.	 		 	PROTEOSTASIS THERAPEUTICS, INC.
					
	By:	 	 /s/ Shunichiro Matsumoto
	 		 	By:	 	 /s/ Meenu Chhabra

		 	 Name: Shunichiro Matsumoto
 Title: Vice
President, Innovation Management
	 		 		 	 Name: Meenu Chhabra
 Title: President and
Chief Executive Officer

  
 3INVESTMENT
AGREEMENT

 

Dated
as of June 2, 2016

 

This
Investment Agreement (“Agreement”) dated as of the date first set forth above (the “Effective Date”) is
entered into by and between New Media Insight Group, Inc., a Nevada corporation (the “Company”), and Atlanta Capital
Partners, LLC (“ACP”), Summit Trading, Ltd. (“Summit”) and Leone Group, LLC (“Leone”, and
each of ACP, Summit and Leone individually an “Investor” and collectively the “Investors”).

 

Now,
therefore, in consideration of the mutual covenants and agreements contained herein, the parties hereby agree as follows:

 

	1.	Funding.

 

	 	(a)	The Investors shall
    provide funds to the Company, on an as-needed basis, and as requested by the Company, of no more than fifty thousand dollars
    ($50,000.00) in lawful money of the United States of America, in the aggregate (individually an “Investment” and
    collectively the “Investments”), for the Company’s use for the monthly transfer agent invoice, accounting
    and auditing costs to maintain Securities and Exchange Commission (“SEC”) reporting requirements, and fees associated
    with obtaining a listing on the OTC Pink level of the OTC Markets, as necessary. No funds invested by the Investors pursuant
    to this Agreement will be utilized for payments to parties related to the Company or for payments to Iconic Holdings, LLC.
	 	 	 
	 	(b)	Upon the completion
    of the audit of the Company for the most recently completed fiscal year, together with the receipt by the Company of a final
    audit report by the auditor, the Investors shall make an Investment in the amount of $5,000.00. For the avoidance of doubt,
    the Investment pursuant to this Section 1(b) shall comprise a part of the total $50,000 investment set forth in Section 1(a).
	 	 	 
	 	(c)	Each Investment
    shall be apportioned pro rata between the Investors as evenly as possible. In the event that an equal apportionment is not
    possible with respect to one Investment, then ACP shall pay the additional amount with respect to the first Investment, Summit
    shall pay the additional amount with respect to the second Investment, and Leone shall pay the additional amount with respect
    to the first Investment, and then the cycle shall repeat as necessary. By way of example and not limitation (i) in the event
    that the first Investment is for $10 in total, ACP shall pay $3.34, Summit shall pay $3.33 and Leone shall pay $3.33; and
    (ii) thereafter, in the event that the second Investment is for $10 in total, ACP shall pay $3.33, Summit shall pay $3.34
    and Leone shall pay $3.33; etc.
	 	 	 
	 	(d)	The Investors may
    apportion a particular Investment between themselves on an alternate basis than as set forth in Section 1(c).
	 	 	 
	 	(e)	The obligations
    of each Investor here are several and not joint. No investor shall have any obligation hereunder to make any Investment not
    made by any other Investor.
	 	 	 
	 	(f)	The Company shall
    provide to each Investor notice of a required Investment pursuant to the provisions as set forth herein, and such Investment
    shall be due and payable no earlier than ten (10) business days following receipt of such notice by the Investors.

 

    	1

    	 

    

 

	1.	Notes. Each
    Investment shall be evidenced by a convertible promissory note (the “Note”), the form of which is attached hereto
    as Exhibit A. Each Note shall be issued in the name of the individual Investor making an Investment.
	 	 
	2.	Effectiveness.
    The effectiveness of this Agreement and the parties’ obligations hereunder (the “Closing”), is conditional
    upon:

 

	 	(a)	The execution by
    the Company and each of the Investors of an agreement between the Company and such Investors providing for the issuance to
    the Investors of an aggregate of 933,334 newly issued shares of common stock to each Investor at a purchase price of $0.001
    per share, and the consummation of the transactions contemplated therein simultaneously with the transactions contemplated
    herein;
	 	 	 
	 	(b)	The execution by
    the Company and Michael Palethorpe of the debt settlement agreement between such parties, and the consummation of the transactions
    contemplated therein simultaneously with the transactions contemplated herein; and
	 	 	 
	 	(c)	The execution by
    Michael Palethorpe and each of the Investors of a stock purchase agreement between Michael Palethorpe and each of the Investors
    providing for the acquisition by the Investors of an aggregate of 16,999,998 shares of restricted common stock of the Company
    for a purchase price of $0.0001 per share, and the consummation of the transactions contemplated therein simultaneously with
    the transactions contemplated herein; and
	 	 	 
	 	(d)	The execution by
    the Company and Michael Palethorpe of the letter agreement between such parties, and the consummation of the transactions
    contemplated therein simultaneously with the transactions contemplated herein.

 

	2.	Representations
    and Warranties. Each Investor, severally and not jointly, represents and warrants to the Company as follows:

 

	 	(a)	Authorization.
    The Investor has full power and authority to enter into this Agreement, to perform his/her obligations hereunder and thereunder
    and to consummate the transactions contemplated hereby and thereby.
	 	 	 
	 	(b)	Binding Obligation.
    Assuming the due execution and delivery of this Agreement by the Company, this Agreement constitutes the valid and binding
    obligation of the Investor, enforceable against the Investor in accordance with its terms, subject, as to enforcement, (i)
    to bankruptcy, insolvency, reorganization, arrangement, moratorium and other laws of general applicability relating to or
    affecting creditors’ rights and (ii) to general principles of equity, whether such enforceability is considered in a
    proceeding in equity or at law.
	 	 	 
	 	(c)	Restricted Securities.
    None of the Notes or the securities issuable on conversion thereof are registered under the Securities Act of 1933, as amended
    (the “Securities Act”), or any state securities laws. The Investor understands that neither the Notes nor the
    securities issuable on conversion thereof may be sold, transferred or otherwise disposed of without registration under the
    Securities Act or an exemption therefrom.

 

    	2

    	 

    

 

	 	(d)	Investment
    Representations.

 

	 	(i)	He/she is making
    the Investment for investment purposes for his own account and not with a view to or for resale in connection with any distribution
    of all or any part of the Investment in violation of the Securities Act of 1933, as amended (the “Securities Act”);
	 	 	 
	 	(ii)	He/she is an accredited
    investor as defined in Rule 501(c) promulgated under the Securities Act, and as such has the financial ability to bear the
    economic risk of making the Investment, has adequate means of providing for his or its current needs and contingencies, and
    has no need for liquidity with respect to the Investment;
	 	 	 
	 	(iii)	He/she has such
    knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of the Investment
    and has obtained, in his judgment, sufficient information regarding the Company’s business and prospects to evaluate
    the merits and risks of the Investment;
	 	 	 
	 	(iv)	In making his/her
    decision to make the Investment, he/she has been advised by his business, tax and legal advisers and is not relying on the
    Company with respect to the business, tax or legal considerations involved in the Investment;
	 	 	 
	 	(v)	He/she understands
    and agrees that he/she must bear the economic risk of his investment for an indefinite period of time because, among other
    reasons, the Investment has not been registered under the Securities Act or under the securities laws of certain states and,
    therefore, cannot be resold, assigned, or otherwise disposed of unless it is subsequently registered under the Securities
    Act and qualified under applicable securities laws of such states or an exemption from such registration and qualification
    is available; and
	 	 	 
	 	(vi)	He/she, if and when
    an Investment is made, is acting as an individual party, and not part of a group, nor acting in concert with any other Investor.

 

	3.	Representations
    and Warranties of the Company. The Company hereby represents and warrants to each Investor as follows:

 

	 	(a)	Authorization.
    The execution, delivery and performance by the Company of this Agreement and the performance of all of by the Company’s
    obligations hereunder have been duly authorized by all necessary corporate action, and this Agreement has been duly executed
    and delivered by the Company. The execution and performance of the transactions contemplated by this Agreement and compliance
    with its provisions by the Company will not conflict with or result in any breach of any of the terms, conditions, or provisions
    of, or constitute a default under, its Certificate of Incorporation or Bylaws or any agreement to which the Company is a party
    or by which it or any of its properties is bound.

 

    	3

    	 

    

 

	 	(b)	Issuance of Shares.
    The issuance and delivery of the Notes and the issuance of the securities upon conversion thereof in accordance with this
    Agreement and the Notes have been duly authorized by all necessary corporate action on the part of the Company, and the securities
    to be delivered pursuant to the Notes, when so delivered, will have been duly and validly authorized and issued by the Company
    and will be fully paid and nonassessable.
	 	 	 
	 	(c)	Binding Obligation.
    Assuming the due execution and delivery of this Agreement by the Investor, this Agreement constitutes the valid and binding
    obligation of the Company, enforceable against the Company in accordance with its terms, subject, as to enforcement, (i) to
    bankruptcy, insolvency, reorganization, arrangement, moratorium and other laws of general applicability relating to or affecting
    creditors’ rights and (ii) to general principles of equity, whether such enforceability is considered in a proceeding
    in equity or at law.

 

	4.	Termination.
    This Agreement may be terminated at any time prior to the Closing:

 

	 	(a)	by the written agreement
    of the parties hereto; or
	 	 	 
	 	(b)	by any party hereto
    if the Closing has not occurred by 5:00 p.m., Eastern time, on June 9, 2016, provided, however, that a party shall not have
    the right to terminate this Agreement pursuant to this subsection 4(b) if such failure of the Closing to have occurred by
    such time shall be due to the breach of this Agreement by such party or the failure of such party to perform or comply with
    any of the covenants, agreements or conditions hereof to be performed or complied with by it on or prior to the Closing.

 

	5.	Miscellaneous.

 

	 	(a)	No Third Party
    Beneficiaries. This Agreement shall not confer any rights or remedies upon any person other than the parties and their
    respective successors and permitted assigns.
	 	 	 
	 	(b)	Entire Agreement.
    This Agreement (including the documents referred to herein) constitutes the entire agreement among the parties and supersedes
    any prior understandings, agreements, or representations by or among the parties, written or oral, to the extent they related
    in any way to the subject matter hereof.
	 	 	 
	 	(c)	Interpretation.
    The parties agree that this Agreement shall be deemed to have been jointly and equally drafted by them, and that the provisions
    of this Agreement therefore shall not be construed against a party on the ground that such party drafted or was more responsible
    for the drafting of any such provision(s). The parties further agree that they have each carefully read the terms and conditions
    of this Agreement, that they know and understand the contents and effect of this Agreement and that the legal effect of this
    Agreement has been fully explained to its satisfaction by counsel of its own choosing.

 

    	4

    	 

    

 

	 	(d)	Governing Law;
    Jurisdiction. This Agreement shall be governed, construed and enforced in accordance with the laws of the State of Nevada,
    without giving effect to principles of conflicts of law. Each of the parties agree to submit to the jurisdiction of the federal
    or state courts located in Clark County, Nevada in any actions or proceedings arising out of or relating to this Agreement.
    Each of the parties, by execution and delivery of this Agreement, expressly and irrevocably (i) consents and submits to the
    personal jurisdiction of any of such courts in any such action or proceeding; (ii) consents to the service of any complaint,
    summons, notice or other process relating to any such action or proceeding by delivery thereof to such party as set forth
    herein and (iii) waives any claim or defense in any such action or proceeding based on any alleged lack of personal jurisdiction,
    improper venue or forum non conveniens or any similar basis. EACH OF THE UNDERSIGNED HEREBY WAIVES FOR ITSELF AND ITS PERMITTED
    SUCCESSORS AND ASSIGNS THE RIGHT TO TRIAL BY JURY IN ANY ACTION OR PROCEEDING INSTITUTED IN CONNECTION WITH THIS AGREEMENT.
	 	 	 
	 	(e)	Specific Performance.
    The parties acknowledge and agree that a breach of the provisions of this Agreement could not adequately be compensated by
    money damages, and therefore any party shall be entitled, in addition to any other right or remedy available to it, to an
    injunction restraining such breach or threatened breach and to specific performance of any such provision of this Agreement,
    and no bond or other security shall be required in connection therewith, and the parties hereby consent to the issuance of
    such an injunction and to the ordering of specific performance.
	 	 	 
	 	(f)	Waiver/Amendments.
    Any waiver by any party to this Agreement of any provision of this Agreement shall not be construed as a waiver of any other
    provision of this Agreement, nor shall such waiver be construed as a waiver of such provision respecting any future event
    or circumstance. No amendment of any provision of this Agreement shall be valid unless the same shall be in writing and signed
    by Palethorpe and the Company.
	 	 	 
	 	(g)	Severability.
    Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect
    the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending
    term or provision in any other situation or in any other jurisdiction.
	 	 	 
	 	(h)	Costs. Each
    party will bear its own costs and expenses incurred in connection with this Agreement and the transaction contemplated thereby.
	 	 	 
	 	(i)	Survival of Terms.
    All representations, warranties and covenants contained in this Agreement or in any certificates or other instruments delivered
    by or on behalf of the parties hereto shall be continuous and survive the execution of this Agreement and the Closing.
	 	 	 
	 	(j)	Assignment.
    This Agreement shall be binding upon the parties hereto and their respective successors and assigns and shall inure to the
    benefit of any assignee, subject to the terms and conditions hereof. Neither party may assign this Agreement without the prior
    written consent of the other party.
	 	 	 
	 	(k)	Notices.
    Notices hereunder shall be given only by personal delivery, registered or certified mail, return receipt requested, overnight
    courier service, by email, and shall be deemed delivered immediately when personally delivered or sent via email (with return
    receipt requested and received) or three days following such notice being deposited in the mail or delivered to a courier
    service, postage or charges prepaid, and properly addressed to the particular party to whom the notice is to be sent, to the
    address as set forth below the applicable party’s name on the signature pages hereto.
	 	 	 
	 	(l)	Headings.
    The headings used in this Agreement are for convenience only and shall not by themselves determine the interpretation, construction
    or meaning of this Agreement.

 

    	5

    	 

    

 

	 	(m)	Attorneys’
    Fees and Costs. In the event any party to this Agreement shall be required to initiate legal proceedings to enforce performance
    of any term or condition of this Agreement, including, but not limited to, the interpretation of any term or provision hereof,
    the payment of moneys or the enjoining of any action prohibited hereunder, the prevailing party shall be entitled to recover
    such sums in addition to any other damages or compensation received, as will reimburse the prevailing party for reasonable
    attorneys’ fees and court costs incurred on account thereof (including, without limitation, the costs of any appeal)
    notwithstanding the nature of the claim or cause of action asserted by the prevailing party.
	 	 	 
	 	(n)	Further Assurances.
    Each party agrees to execute and deliver to the other such additional documents and instruments, and to do and perform such
    other acts and things, as may be reasonably necessary for effecting the transactions contemplated herein.
	 	 	 
	 	(o)	Counterparts.
    This agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together
    shall constitute one and the same instrument.
	 	 	 
	 	(p)	Tax Withholding.
    In the event that the Company is required by law or governmental authority to pay or withhold any federal or state tax attributable
    to distributions or allocations to the Investor, the Company may pay or withhold such funds out of any distributions or payments
    payable to Investor (which withholding shall be treated for all purposes as an actual distribution or paid to the Investor).

 

[Signatures
appear on following page]

 

    	6

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.

 

	 	New Media Insight Group, Inc.
	 	 	 
	 	By:	 
	 	Name:	Michael Palethorpe
	 	Title: 	Chief Executive Officer
	 	 	 
	 	Address for Notices:
	 	 	 
	 	New Media Insight Group, Inc.
	 	 	 
	 	Attn: Michael Palethorpe
	 	28202 N 58th Street
	 	Cave Creek, AZ 85331
	 	Email: michaelpalethorpe@gmail.com

 

	Summit
                           Trading, Ltd.

        By:
        Daryl Orenge, its Attorney in Fact
	 	Leone
                           Group, LLC

        By:
        Laura Anthony, Sole Member

	 	 	 
	 	 	 
	Address
    for Notices:	 	
	 	 	Address
    for Notices:
	 	 	 
	 	 	 
	 	 	 
	Email:
    callcharlesarnold@gmail.com	 	Laura
        Anthony

        c/o
        Legal & Compliance, LLC

        330
        Clematis Street, Suite 217

        West
        Palm Beach, FL. 33401

        Email:
        Lanthony@legalandcompliance.com

 

	Atlanta Capital Partners, LLC	 
	 	 	 
	By:	David Kugelman, its	 
	 	 	 
	 	 	 
	Address for Notices:	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	Email: dk@atlcp.com	 

 

    	7

    	 

    

 

Exhibit
A

 

Form
of Promissory Note

 

(Attached)

 

    	8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}]]